RUZURGI® IS NOW AVAILABLE AND COVERED BY THE VAST MAJORITY OF PUBLIC HEALTH AND PRIVATE INSURANCE PLANS
BLAINVILLE, Quebec (Canada) – July 11th, 2023 – Médunik Canada, member of Duchesnay Pharmaceutical Group, is pleased to announce that Ruzurgi® (amifampridine) is now covered by the vast majority of provincial and federal public health programs and many private insurance plans through special authorization. More than 90% of Canadians suffering from Lambert-Eaton Myasthenic Syndrome (LEMS) will benefit from this extensive coverage.